Bilayer Therapeutics, Inc.
Monday, June 03, 2024
Company Presentation
![Metabolic Diseases](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 2
Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat several diseases of the colon using an incretin-based mechanism of action and a unique and proprietary colonic delivery technology developed in Bob Langer’s lab at MIT. BL-050, an orally available therapy for metabolic disorders such as obesity and diabetes, acts through increasing native levels of GLP-1, GLP-2, PYY, glucagon, neurotensin, OXM, and CCK. BL-010, also orally available, acts on the receptor TGR5 and has the potential to treat several types of chronic constipation. There are additional product candidates.
![Bilayer Therapeutics, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1801771-1-JPG.png)
Company Website:
http://www.bilayer-therapeutics.com
Lead Product in Development:
BL-050 for metabolic disorder (obesity/diabetes)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Cambridge
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
Thomas A. Collet
Development Phase of Primary Product
Pre-Clinical
Primary Speaker